The Looksmaxxing Research Stack
Body recomposition is the foundation of aesthetic optimization. GLP-1/GIP dual agonists represent the most clinically validated intervention available. This is the compound class behind Clavicular's viral protocol.
The Looksmaxxing Hierarchy
Clavicular and the looksmaxxing community figured this out before mainstream media. The clinical data backs the hierarchy.
Body Composition
Highest LeverageGLP-1/GIP dual agonists dominate this tier. Reducing visceral and subcutaneous adiposity reshapes facial structure, jawline definition, and overall frame. SURMOUNT-1 data shows 22.5% mean body weight reduction over 72 weeks. No other research compound class approaches this magnitude of effect.
Skin Quality
Secondary PriorityCollagen density and dermal thickness determine skin tightness and texture. Reduced adiposity alone significantly improves periorbital and facial skin definition. Secondary interventions in this tier complement the foundational recomposition work.
Recovery and Training
Supporting FactorTissue repair efficiency and training adaptations support lean mass preservation during recomposition phases. DXA sub-studies from SURMOUNT trials confirm lean mass is largely preserved during tirzepatide protocols — a critical differentiator from simple caloric restriction.
Choose Your Protocol
All stacks include bacteriostatic water for reconstitution.
Begin your body recomposition research. Full 15mg vial covers the complete titration sequence.
- Full 15mg tirzepatide vial
- Covers complete titration sequence
- Bacteriostatic water included
- Lowest research entry cost
The extended research protocol. 30mg provides 2x the research duration. Mirrors the compound class used in Clavicular's documented protocol.
- 30mg — 2× research duration
- Mirrors Clavicular compound class
- Best mg-per-dollar of the two core options
- Bacteriostatic water included
Full 6-month research supply. Most cost-efficient mg-per-dollar. For serious long-duration research protocols.
- 60mg — full 6-month supply
- Best overall mg-per-dollar
- Long-duration research protocols
- Bacteriostatic water included
Why GLP-1/GIP Dual Agonists for Body Recomposition
The clinical data supporting tirzepatide for aesthetic body recomposition is now among the most robust in metabolic research. Here is what the Phase 3 trials show.
Dual Receptor Activation
Tirzepatide simultaneously activates GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual incretin mechanism produces synergistic effects on energy balance and adipose tissue mobilization that neither receptor pathway achieves alone.
Lean Mass Preservation
DXA body composition sub-studies from SURMOUNT trials confirm that the majority of weight lost during tirzepatide protocols is fat mass. Lean mass is largely preserved — a critical differentiator from simple caloric restriction, which causes significant muscle loss.
Visceral Fat Reduction
Visceral adipose tissue — the fat depot most responsible for abdominal and facial aesthetic outcomes — is disproportionately reduced. Visceral fat reduction drives improvements in jawline definition, facial bone structure visibility, and abdominal vascularity.
47% Greater Loss vs Semaglutide
SURMOUNT-5 head-to-head trial data: tirzepatide produces 47% greater weight loss than semaglutide at comparable doses. The GIP receptor co-activation appears to enhance fat oxidation and adipocyte metabolism beyond what GLP-1 monotherapy achieves.
The Clavicular Connection
Clavicular's viral looksmaxxing protocol documents the use of a GLP-1/GIP dual receptor agonist — the same compound class as tirzepatide. The protocol's documented results align with Phase 3 trial data. The looksmaxxing community arrived at the same conclusion as the clinical literature.
SURMOUNT-1 Outcomes at 72 Weeks
Phase 3, n=2,539. Mean body weight reduction: 15.0% (5mg), 19.5% (10mg), 22.5% (15mg) vs 2.4% placebo. 57% of subjects at 15mg achieved ≥20% body weight reduction. These are the largest weight reduction outcomes documented in any pharmaceutical trial to date.
Standard Titration Schedule
The SURMOUNT trial titration sequence, escalating every 4 weeks to maintenance dosing at week 21+.
| Period | Dose | Phase |
|---|---|---|
| Week 1–4 | 2.5mg | Initial tolerance phase |
| Week 5–8 | 5mg | First escalation |
| Week 9–12 | 7.5mg | Mid-titration |
| Week 13–16 | 10mg | Upper mid-range |
| Week 17–20 | 12.5mg | Pre-maintenance |
| Week 21+ | 15mg | Maintenance dose |
Need reconstitution calculations?
BAC water volume, concentration, and dosing calculator
Looksmaxxing Stack — Common Questions
What is the looksmaxxing peptide stack?
The looksmaxxing peptide stack centers on GLP-1/GIP dual agonists — specifically tirzepatide — for body recomposition. Body composition is the single highest-leverage variable in aesthetic optimization: reducing visceral and subcutaneous fat while preserving lean mass reshapes the face, jaw, and overall frame more dramatically than any other intervention. The clinical data from SURMOUNT-1 (72 weeks, n=2,539) shows mean weight reductions of up to 22.5% at the 15mg dose.
Is tirzepatide the same compound Clavicular uses?
Clavicular's documented protocol uses a GLP-1/GIP dual receptor agonist — the same compound class as tirzepatide. The mechanism (dual incretin receptor activation) is identical. Tirzepatide is the Phase 3-validated compound in this class with the most robust clinical dataset, including SURMOUNT-1 through SURMOUNT-4 trials covering over 5,000 subjects.
How long is a research protocol?
The standard titration protocol runs 21+ weeks to reach maintenance dosing. Week 1-4 at 2.5mg, escalating every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to 15mg at week 21+. The GLP-2 T 30mg vial (Clavicular Protocol Stack) provides approximately 2x the research duration of the 15mg starter vial at superior mg-per-dollar efficiency.
What results does the clinical data show?
SURMOUNT-1 (Phase 3, 72 weeks): mean body weight reduction of 22.5% at 15mg versus 2.4% placebo. 57% of subjects achieved ≥20% body weight reduction. DXA sub-studies confirmed the majority of weight lost was fat mass, with lean mass largely preserved. Visceral adipose tissue — the primary determinant of abdominal and facial aesthetics — was disproportionately reduced.
Why is the GLP-1/GIP dual agonist better than semaglutide for looksmaxxing?
Head-to-head data from the SURMOUNT-5 trial shows tirzepatide produces 47% greater weight loss than semaglutide at comparable doses. The GIP receptor co-activation appears to enhance fat oxidation and may provide additional lean mass-sparing effects beyond GLP-1 monotherapy. For body recomposition — the core looksmaxxing intervention — the dual agonist mechanism delivers measurably superior outcomes.
Related Research
SURMOUNT Trial Data
Full Phase 3 data breakdown — SURMOUNT-1 through SURMOUNT-5 outcomes.
Reconstitution Guide
Step-by-step protocol for BAC water reconstitution and storage.
All Research Stacks
Compare all tirzepatide research stack configurations and pricing.
Start Your Research Protocol
The Clavicular Protocol Stack — 30mg GLP-2 T with bacteriostatic water — is the most popular starting point for extended looksmaxxing research.